Limiting Severe Outcomes and Impact on Intensive Care Units of Moderate-Intermediate 2009 Pandemic Influenza: Role of Infectious Diseases Units

Sergio Carbonara*, Giuseppe Bruno, Giuseppe Di Ciaula, Anna Donata Pantaleo, Gioacchino Angarano, Laura Monno

Clinic of Infectious Diseases, School of Medicine and Surgery, University of Bari, Bari, Italy

Abstract

Purpose: The rate of severe outcomes of patients with 2009 pandemic (A/H1N1) influenza (2009pI) hospitalized in non-intensive care units (ICUs) has not been defined thus far. This study aims to assess the efficacy of the management of patients with influenza-like illness (ILI) of moderate intermediate severity in an infectious diseases unit (IDU) during the first wave of 2009pI and its influence on the burden of ICUs.

Methods: All patients hospitalized from October 27, 2009, to February 5, 2010, with ILI were included in this prospective observational study. The IDU was organized and the staff was trained to provide intermediate care; patients were transferred to the ICU only if they required invasive ventilation, extracorporeal membrane oxygenation, or advanced cardiovascular support. Demographic data, clinical presentation, coexisting medical conditions, and laboratory and radiological findings were recorded and analyzed, as well as treatment and outcome data.

Results: Overall, 108 patients (median age 36 years [IQR 27–54], 57.4% males) including 66.7% with ≥1 risk factor for severe influenza, 47.2% with confirmed 2009pI by RT-PCR and 63.9% with pneumonia, were enrolled in the study. All subjects received intravenous fluids and 83.3% were administered oseltamivir, 96.3% antibacterials, 19.4% oxygen therapy without ventilatory support, and 10.2% non-invasive ventilation. A total of 106 (98.1%) subjects were discharged after a 6-day median hospital stay [IQR 4–9]. Two patients (1.9%) were transferred to the ICU. There were no deaths.

Conclusions: These results suggest that the aggressive treatment of patients with moderate intermediate severity 2009 pandemic ILI in non-ICU wards may result in a low rate of severe outcomes and brief hospitalization. IDUs, if properly organized for intermediate care, may efficiently provide correct disease management, in addition to complying with infection control requirements, thus reducing the burden of the pandemic on ICUs. Further studies are warranted to evaluate the outcome of patients with moderate intermediate 2009pI in different non-ICU settings.

Introduction

Despite its rapid spread among the population worldwide, the 2009pI was characterized by overall moderate severity, with higher rates of asymptomatic and mild cases in comparison to previous pandemics and several interpandemic influenza outbreaks [1]. Notwithstanding, a remarkable burden of patients with differing grades of clinical severity resulted, seriously challenging health services, including hospitals and, in particular, intensive care units [ICUs] [2,3]. Low infection rates occurred among the elderly population [1,4], and consequently most hospitalized patients, including those with severe outcomes (e.g., ICU admission and death), were young and middle-aged adults [1,3–8], although a correlation between increasing severity and age was evident. According to the European Centre for Disease Prevention and Control (ECDC), around 80% of deaths in Europe occurred in patients under the age of 65 years [1]; in the USA, approximately 90% of estimated hospitalizations and 87% of estimated deaths occurred in people younger than age 65 [7]. Worldwide, the median age was 19, 42 and 46 years among hospitalized patients, those admitted to ICUs, and fatal cases, respectively [4]. The risk of death in hospitalized patients, however, was highest in those older than 64 years [4,7]. Furthermore, the risk for complications and severe outcomes was associated with the presence of chronic diseases or other factors such as obesity and pregnancy [4,8]. Nonetheless, underlying risk conditions were not detected in 28-69% of patients hospitalized in non-ICUs [4,5,8], and in 22-48% of those who either were admitted to the ICU or died [4,5,8,9]; ECDC reports that around 25–30% of deaths attributed to the pandemic in Europe were in entirely healthy young adults and outside the traditional risk groups [1].
Several large surveillance studies from differing global areas, conducted among hospitalized patients during the first wave of 2009pI [3–5,8,10–16], have described the risk factors for severe outcomes, reporting an ICU admission rate of 14–27% and an overall mortality of 4–6%. However, to our knowledge, the rate of severe outcomes among 2009pI patients admitted to medical units has never been defined, as the above studies do not distinguish between those patients directly admitted to ICUs after presentation to hospital or emergency services from those transferred to the ICUs following a period in non-ICU wards; in addition, the mortality rate was not specified for each setting.

The present study aims to describe the outcomes and impact on ICUs of patients with moderate-intermediate severity influenza-like illness (ILI) who were hospitalized during the first wave of 2009pI in an infectious diseases unit (IDU) capable of providing an intermediate-level of care, along with the necessary measures for infection control, and specialized management of the infection and its complications.

Methods

Ethics Statement

Each patient provided informed written consent for the collection, recording, analysis and publication of data for the present study. The study was sent to the hospital Ethical Committee, which, according to Italian regulations regarding observational studies [17], is not required to provide formal ethical approval.

The clinic of Infectious Diseases of the University of Bari is located in the largest hospital (1,550 beds) of the Apulia Region of Southern Italy. The inpatient unit of the clinic is composed of 22 beds served continuously by six infectious diseases specialists, and is designated by the regional pandemic plan as a reference institution for the hospital care of ILI patients requiring a moderate to intermediate level of care; this regional plan provides for limiting admission to ICUs to those patients requiring invasive mechanical ventilation, extracorporeal membrane oxygenation (ECMO) or advanced cardiovascular support. The above role assigned to our clinic was motivated both by the specialized competence of this unit for management of infectious diseases, and its compliance with the structural and organizational standards recommended to ensure adequate infection control. These structural characteristics included the availability of 14 beds located in eight airborne infection isolation rooms. Furthermore, the IDU was specifically organized and the staff trained to provide intermediate care for influenza complications, including the assessment of need for emergency oxygen supplementation and non-invasive ventilation (NIV) support, as well as administration, monitoring and discontinuation of these measures. At the start of the pandemic season, the nurse:patient ratio of the unit was increased from the usual 1:5.5 to 1:3 in the areas dedicated to intermediate care. When necessary, an intensive-care specialist consultation and transfer to ICUs were readily available.

All consecutive patients hospitalized with an ILI diagnosis from October 27, 2009, to February 5, 2010, (date of the last patient admission during the 2009–2010 pandemic influenza season) were enrolled in this prospective observational study. Diagnosis was based on the following criteria for the definition of ILI established by the Italian Ministry of Health [18]: acute respiratory disease with an abrupt onset with fever ≥38°C, at least one respiratory symptom (among cough, pharyngodynia, nasal congestion) and at least one of the following symptoms: headache, general malaise, asthenia, chills, sweats. At admission, the following were obtained from all patients: chest radiographs, assessment of vital signs including pulse oximetry, supplemented when necessary by arterial blood gas (ABG) measurements, and nose and throat swabs for presence of the 2009pI virus by real-time reverse-transcriptase polymerase chain reaction (RT-PCR) [19,20]. All patients were asked to undergo blood and sputum cultures before initiating antibiotics. Tests for Legionella pneumophila and Staphylococcus pneumoniae urinary antigens were carried out in patients with pneumonia. Other microbiological investigations were performed on an individual basis according to specific clinical findings. All women of reproductive age who did not declare ongoing menses or pregnancy underwent a quantitative human chorionic gonadotropin blood test. Each patient provided an informed written consent for the collection, recording and analysis of data for the present study, which included the following: demographic information, body-mass index (BMI), cigarette and alcohol use, influenza vaccination, underlying medical conditions, immunosuppressive therapies prior to admission, symptoms related to the current hospitalization and their onset, clinical signs, chest radiograph and other imaging techniques, laboratory tests, antiviral and antibacterial treatments, steroid and other concomitant therapies, oxygen supplementation, NIV and cardiovascular support. Outcomes were classified as either hospital discharge, transfer to ICU or death; hospital length-of-stay was also recorded.

Definitions

“Moderate-Intermediate disease” was defined as the presence of any of the following: arterial blood pH<7.35 or >7.45, respiratory rate >25 breaths/min or oxygen saturation <94% or arterial partial pressure of oxygen <8 Kpa when breathing room air, heart rate >110 beats/min, white blood cells count <4,000/μL or >12,000/μL, other evidence of organ dysfunction for which hospitalization was required. Within this category, we distinguished patients with moderate from those with intermediate severity based on the level of care required. In particular, “Moderate disease” was defined as an illness requiring a normal ward care only, whereas “Intermediate disease” was defined as the presence of serious organ dysfunction which, although not necessitating ICU admission, required higher care level (“intermediate care”) than the normal ward care. This higher level of care included: prolonged high-flow oxygen supplement, NIV, intravenous drugs for inotropic/vasopressor support or to control cardiac arrhythmias, close monitoring of the patient (continuous non-invasive polyfunctional monitoring of vital parameters, continuous video-monitoring of the patient bed, a minimum of hourly patient observation), frequent assessment (>2 times daily) of laboratory parameters (e.g., ABG, cardiac enzymes, hepatic or renal function tests), chest drainage as required.

“Severe outcome” was defined as ICU admission or death, and “Severe disease” as a critical illness with a severe outcome.

“Risk factors for severe influenza” were defined as any chronic medical condition such as pulmonary, cardiovascular, renal, hepatic, neuromuscular, hematologic, and metabolic disorders; malignancies, immunodeficiency; elderly (aged >65 years); pregnancy, obesity (BMI≥30) [3–5,8,12,21–23].

According to the IDSA (Infectious Diseases Society of America) and BTS (British Thoracic Society) criteria [24,25], “Pneumonia” was defined as a pulmonary infiltrate demonstrated by chest radiograph or other imaging technique, not known to be previously present and for which there was no other explanation than infection, in addition to clinical features consistent with an acute lower respiratory tract infection.
Results

Overall, 108 patients were included in the analysis. The characteristics of these patients are illustrated in Tables 1, 2, 3. In particular, median age was 36 years [IQR 27–54], and 62 subjects (57.4%) were males. Seventy-two patients (66.7%) had ≥1 risk factor for severe influenza. Six women were either pregnant or puerperal; a BMI ≥30 was detected in 19 subjects (17.6%), and at least one chronic co-morbidity was noted in 59 patients (54.6%).

Median time from onset of symptoms to IDU admission was 3 days [IQR 2–3]. Pneumonia was radiologically confirmed in 69 cases (63.9%), 12 of whom (17.4%) showed an interstitial pattern while 57 (82.6%) had a lobular pattern. Positive microbiological analyses are reported in Table 2. RT-PCR for 2009pI virus performed on nasal and/or pharyngeal swabs resulted positive in 51 (47.2%) subjects. Overall, 16 patients (14.8%) showed a microbiologically confirmed bacterial co-infection. Blood cultures were performed in 100 patients, yielding isolation of methicillin-sensitive Staphylococcus aureus in 2 cases, Escherichia coli in 1 and Staphylococcus hominis in another. Only 27 patients produced sputum samples for culture, three of which were positive (Staphylococcus haemolyticus in 2 patients and Mycobacterium fortuitum in 1). L. pneumophila urine antigen was detected in one patient. No patient resulted positive for S. pneumoniae urine antigen. Four of seven patients with urinary tract infection demonstrated a significant growth of E. coli from urine. Culture of pharyngeal swabs was positive in the remaining four subjects (Streptococcus pyogenes in 2, S. aureus in 2).

The findings of clinical severity are illustrated in Table 3. A total 100/108 patients (92.6%) met criteria for moderate-intermediate severity, 21 of whom (21.0%) met criteria for intermediate severity; 105/108 subjects (97.2%) had at least one finding of moderate-intermediate severity or at least one risk factor for severe influenza. The remaining three patients (2.8%) were hospitalized only for social reasons.

Therapy with oseltamivir was initiated in 90 patients (83.3%) within 12 hours after admission. Antibacterials were administered to 104 subjects (96.3%) and corticosteroids to one patient only. The antibacterial regimens most frequently used were the following: beta-lactam plus a respiratory fluoroquinolone (27.8%), a macrolide alone (25.0%), a respiratory fluoroquinolone alone (16.7%), and a beta-lactam plus a macrolide (12.0%). Reasons for prescribing antibiotics were one or more of the following: demonstrated bacterial disease; persistence, worsening or relapse of high fever or other relevant ILI clinical signs; pneumonia; exacerbation of chronic obstructive pulmonary disease; other serious clinical conditions in which a bacterial co-infection was deemed possible; immune-deficiency or other relevant risk factors for severe influenza. Median duration of antibiotic therapy was 7 days [IQR 5–9], with no significant difference between patients in whom RT-PCR for 2009pI virus was positive and those remaining.

All patients received hydro-saline intravenous fluids, 21 (19.4%) required oxygen therapy but no ventilatory support, and 11 (10.2%) were administered non-invasive ventilatory support: continuous positive airways pressure (CPAP) in nine cases and bilevel positive airways pressure (BiPAP) in two.

A total of 106 patients (98.1%) were discharged following fever remission and either normalization or marked improvement of the remaining acute alterations detected at presentation. The median hospital length-of-stay was 6 days [IQR 4–9]. There were no deaths. Two female patients (1.9%) were transferred to the ICU after 1 and 10 days, respectively, following admission to the IDU ward; the transfer to ICU was due to development of an acute respiratory distress syndrome necessitating intubation and invasive ventilation in both cases; one patient was also subjected to ECMO. One of these two subjects was 47 years old and showed no risk factor for severe influenza; the second patient, aged 55, had a body mass index of 40 and suffered from COPD.

Discussion

The 2009pI created a sudden increase in the demand for access to hospital facilities; in particular, the capacity of ICUs to care for critically ill patients was seriously challenged [2,3,10,15,26,27]. Several large multi-center studies from different continents have reported that nearly 14–27% of all patients hospitalized during the first 2009pI wave were admitted to ICUs and mortality ranged from 4% to 6% [3–5,8,10–16]. However, these same studies did not specify the rate of transfers to ICUs or the mortality among patients admitted to non-intensive care units; moreover, the frequency of these adverse outcomes is not known for patients admitted to the various specific non-intensive care units (e.g., intermediate-care/high-dependency units, infectious disease clinics, respiratory wards, or other general or specialized medical departments). This information would assist policy makers in determining the suitability of different non-ICU hospital settings to manage moderate to intermediate severity illness, and the role of some of these settings to safely reduce the ICU patient burden and ICU-associated risks and costs.

The present prospective observational study aimed to report the outcome of patients hospitalized in an IDU with moderate-intermediate ILI severity during the initial 2009pI wave. An ulterior objective of our study was to clarify to what extent this type of specialized unit could effectively serve to decrease the 2009pI ICU patient burden, both by limiting the ICU transfer rate of patients initially hospitalized in a medical ward and by providing, when needed, an intermediate-level of care. These roles were assigned to our IDU by the Apulia regional pandemic plan, which limited the admission to ICUs only to patients necessitating invasive ventilation, ECMO or advanced cardiovascular support.

Our results demonstrate an extremely low-rate of severe outcomes, as 98.1% patients were discharged in clinically stable conditions, only 1.9% required an ICU transfer, and no deaths occurred. Furthermore, we registered a brief median-hospital-recovery (6 days [IQR 4–9]). Notably, more than one-half of our patient population showed at least one risk factor for severe influenza, 92.6% at least one criterion of moderate intermediate clinical severity, 63.9% a pneumonia, and 29.6% necessitated either acute oxygen supplement or non-invasive ventilation support. In addition, one of the two ICU-transferred patients had two co-existing risk factors for a severe outcome and was transferred just one day after IDU admission, suggesting that her outcome would not have been influenced by our unit care. Unfortunately, as mentioned above, similar studies providing appropriate outcome data for patients hospitalized in medical units to serve as comparison have yet to be published to our knowledge; the length of hospital stay is the only information that the length of hospital stay is the only information reported by a prior study of patients not admitted to an ICU, and reported a result (5-day median [IQR 3–7]) similar to our observation [5]. Our population resembled a vast proportion of patients admitted to non-intensive care units; moreover, the frequency of these adverse outcomes is not known for patients admitted to the various specific non-intensive care units (e.g., intermediate-care/high-dependency units, infectious disease clinics, respiratory wards, or other general or specialized medical departments). This information would assist policy makers in determining the suitability of different non-ICU hospital settings to manage moderate to intermediate severity illness, and the role of some of these settings to safely reduce the ICU patient burden and ICU-associated risks and costs.

Outcomes of 2009 Pandemic Influenza
### Table 1. Epidemiological and clinical characteristics of 108 consecutive patients with influenza-like illness hospitalised in an infectious diseases unit during the 2009/10 wave of 2009 pandemic (A/H1N1) influenza.

| Characteristics                          | Patients |
|------------------------------------------|----------|
|                                          | #        | %  |
| **Age (years)**                          |          |    |
| median (IQR)                             | 36       | (27–54) |
| 16–30                                    | 39       | 36.1 |
| 31–50                                    | 39       | 36.1 |
| 51–65                                    | 17       | 15.7 |
| >65                                      | 13       | 12.1 |
| **Sex (male)**                           |          |    |
|                                          | 62       | 57.4 |
| **Race**                                 |          |    |
| White                                    | 98       | 90.7 |
| African                                  | 10       | 9.3 |
| **Smoking**                              |          |    |
|                                          | 27       | 25.0 |
| **Risk factors for severe influenza**    |          |    |
| ≥1 risk factor                           | 72       | 66.7 |
| BMI ≥30                                  | 19       | 17.6 |
| Age >65                                  | 13       | 12.0 |
| Pregnancy/puerperium                     | 6        | 5.6 |
| **Chronic co-morbidities**               |          |    |
| COPD                                     | 15       | 13.9 |
| asthma                                   | 14       | 13.0 |
| cardiovascular disease                   | 19       | 17.6 |
| diabetes mellitus                        | 8        | 7.4 |
| chronic hepatitis                        | 9        | 8.3 |
| chronic renal failure                    | 5        | 4.6 |
| cancer                                   | 5        | 4.6 |
| autoimmune disease                       | 4        | 3.7 |
| HIV-infection                            | 2        | 1.9 |
| other 1                                 | 7        | 6.5 |
| ≥1 chronic co-morbidity                  | 59       | 54.6 |
| **Seasonal flu vaccination**             |          |    |
|                                          | 6        | 5.6 |
| **ILI Symptoms**                         |          |    |
| Fever ≥38 °C                             | 108      | 100 2 |
| Asthenia                                 | 87       | 80.6 |
| Cough                                    |          |    |
| non productive                           | 47       | 43.5 |
| productive                               | 32       | 29.6 |
| cough, any                              | 79       | 73.1 |
| Rhinorrhoea                              | 7        | 6.5 |
| Myo-Arthralgiae                          | 43       | 39.8 |
| Headache                                 | 33       | 30.6 |
| Pharyngodynia                            | 29       | 26.9 |
| Chest ache                               | 25       | 23.1 |
| Gastrointestinal symptoms                |          |    |
| nausea, vomiting                         | 26       | 24.1 |
| diarrhoea                                | 8        | 7.4 |
| gastrointestinal, any                    | 26       | 24.1 |
| **Time from symptom onset to hospitalization (days)** |          |    |
| median (IQR)                             | 3        | (2–3) |
| **Pneumonia**                            |          |    |
| any chest radiograph pattern             | 69       | 63.9 |
| interstitial pathology                   | 12       | 17.4 4 |
| lobular pathology                       | 57       | 82.6 4 |

NOTES:
1. Data refer to percent of total number of patients, unless otherwise specified.
2. Fever ≥38 °C was a necessary criteria for defining an influenza-like syndrome and, consequently, for the inclusion in the study.
3. Other comorbidities: neurologic disease (1 patient), hypothyroidism (3 patients), hemoglobinopathy (2 patients), glucose-6-phosphate dehydrogenase deficiency (1 patient).
4. Percentage is calculated using the total number of pneumonia patients as denominator.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus; IQR, interquartile range; RT-PCR, reverse transcription polymerase chain reaction.

doi:10.1371/journal.pone.0042940.0001
A total of 104/108 (96.3\%) of our patients were treated with antibiotics, although a bacterial co-infection was demonstrated only in 14.8\% of cases; this low bacterial yield might have been influenced by the antibiotics often administered to patients before their hospital admission. Indications for empirical antibiotic therapy, specified in the Results section, were consistent with current recommendations for antibacterial use in 2009pI [28,29]. Other series [3,6,30] have reported an extensive use of antibiotics (82–98\%) in confirmed 2009 H1N1-infected patients, despite the fact that a bacterial infection was documented only in 3–8\% cases. Nonetheless, we acknowledge that the broad antibiotic prescription or duration in our patients might have been partly unjustified. However, this extensive usage was influenced (in particular during the first wave of 2009pI) by the following issues: i) debates and scarce evidence regarding indications for empirical antibiotic treatment in the 2009pI patients [31]; ii) the major role of bacterial pneumonia as cause of death during prior influenza pandemics [32,33]; iii) the possibility that bacterial co-infections may occur early in the development of 2009pI severe illness [28] and considerably contribute to severe outcomes [34,35]. Moreover, only a minority of influenza-related lower respiratory tract infections are defined microbiologically [24]; based on several reports of 2009pI-associated pneumonia, a bacterial co-infection cannot be demonstrated in most [6] or any patient [36,37], and can remain undiscovered in up to 29\% of cases, being identified only post-mortem [30]. Thus, it has been postulated that a low number of reported bacterial pneumonia during 2009pI might reflect the difficulty of documenting a specific bacterial diagnosis rather than an actual low incidence [3,38]. Finally, the use of macrolides has been favored due to the adjuvant anti-inflammatory and immunomodulatory activity observed for these molecules in respiratory tract infections [39] including community acquired pneumonia (CAP) [40] and seasonal influenza [41–45], and proposed for 2009pI as well [46]. Altogether, these considerations call for further studies aiming to improve the indications for empiric antibiotic use in patients hospitalized with pandemic influenza. The median duration of antibacterial treatment in our population (7 days overall) was not shorter in patients with a positive RT-PCR for 2009pI virus, most likely because of the awareness of a possible non-microbiologically evident bacterial co-infection, as discussed above; furthermore, RT-PCR results for 2009pI virus were often available only late in the patient’s clinical course due to an extensive laboratory work-load.

A possible limitation of our study is that only 47\% of subjects had confirmed 2009pI with RT-PCR on nasal and pharyngeal swabs. This result, however, is consistent with published data regarding the performance of this virological analysis; in fact, de la Tabla et al [47] reported 44\% positivity with this procedure for patients with pandemic ILI. On the other hand, the possibility that the ILI cases negative on 2009pI RT-PCR in our population were due to seasonal influenza viruses was negligible, as the pandemic virological surveillance conducted in Italy during the first pandemic season [48] demonstrated that the 2009pI virus was responsible for 95.6\% of all confirmed cases of influenza. A portion of our patients might have been infected by non-influenza respiratory viruses; however, this possible bias would not have involved a significant number of the study population when considering the following: a) the study was performed during the overwhelming first wave of 2009pI, b) all patients presented with an acute febrile illness corresponding to ILI-defining criteria, c) the moderate intermediate, rather than mild, clinical severity and d) the adult age of patients. In any case, ILI patients with a non-confirmed 2009pI virus infection were included in this study because we believe that this option better reflects the “in the field”
situation of clinical practice in units involved in the management of these patients. As a matter of fact, after the first weeks of the pandemic, international health authorities no longer recommended routine RT-PCR tests for the 2009pI infection among hospitalized subjects, limiting this approach to specific conditions (e.g., critical patients) [49,50]. The present study was observational, and this represents a further limitation versus a case-control analysis, such as comparing the outcomes of our patients to those of a similar population admitted to a non-IDU/non–ICU medical unit; these types of studies are currently lacking although highly warranted.

Notwithstanding the possible study limitations discussed above, our data suggest that early and aggressive treatment of patients hospitalized for moderate intermediate 2009pI illness with oseltamivir, antibacterials and support measures including, when appropriate, intravenous fluid restoration, emergency oxygen therapy and NIV, may yield a very low rate of severe outcomes in terms of ICU transfer and mortality, with a brief hospital stay. At the same time, our results might indicate that IDUs can contribute to reducing the burden of 2009pI in ICUs, by efficiently caring for patients requiring intermediate care. However, proper organization and staff training are required for IDUs to deliver an intermediate assistance level, including the correct assessment for use of acute oxygen therapy and NIV support, as well as the correct administration, monitoring and discontinuation of these treatments [51–53]. Furthermore, intensive-care specialist consultation and transfer to ICU should be readily available to these medical units.

If confirmed by further studies, our observations suggest that implementing similar IDUs or other different specialized medical units, such as those dedicated to intermediate care (high-dependency units, HDUs), might optimize the outcome of patients with moderate-intermediate severity pandemic ILI and limit the burden of these patients on ICUs. However, many hospitals (most hospitals in Italy) are not equipped with HDUs. Consequently, patients hospitalized because of complicated 2009pI requiring intermediate care are admitted either into ICUs, thereby increasing both the utilization of this limited hospital resource and ICU-related risks and costs, or into medical wards which are not adequate to provide the required intermediate-level of care, thus possibly resulting in an excessive and unjustified rate of severe

### Table 3. Findings of moderate intermediate severity in 108 patients with influenza-like illness during the 2009/10 wave of the 2009 pandemic (A/H1N1) influenza.

| Findings                                | Patients |
|-----------------------------------------|----------|
|                                         | #        | %   |
| Respiratory                             |          |     |
| Pneumonia                               | 69       | 63.9|
| Pleural effusion                        | 12       | 11.1|
| Exacerbated COPD/Asthma                 | 24       | 22.2|
| Arterial blood pH<7.35 or >7.45         | 58       | 53.7|
| Respiratory rate >25/min                | 30       | 27.8|
| SpO2 <94% or PaO2<8 Kpa                 | 22       | 20.4|
| Cardiovascular                          |          |     |
| Acute or exacerbated chronic heart failure | 7   | 6.5 |
| Myo/pericarditis                        | 2        | 1.9 |
| Arrhythmia/electrocardiographic alterations | 15  | 13.9|
| Severe dehydration                      | 22       | 20.4|
| Heart rate >110/min                     | 29       | 26.9|
| Blood pressure: systolic <90 mm Hg or diastolic ≤60 mm Hg | 17 | 15.7|
| Elevated myocardial enzymes             | 18       | 16.7|
| Renal                                   |          |     |
| Acute or exacerbated chronic renal failure/Dialysis | 15 | 13.9|
| Elevated blood urea nitrogen            | 15       | 13.9|
| Electrolyte imbalance                   | 9        | 8.3 |
| Hepatic                                 |          |     |
| Acute hepatitis or exacerbated chronic liver disease | 6 | 5.6 |
| Neurological                            |          |     |
| Decreased consciousness                 | 5        | 4.6 |
| Haematological                          |          |     |
| WBC <4,000 or >12,000/μL                | 31       | 28.7|
| HGB <10 g/dL                            | 10       | 9.3 |
| Gastrointestinal                        |          |     |
| Severe vomit/inability to maintain oral intake | 13 | 12.0|
| Sepsis                                  | 3        | 2.8 |
| ≥1 finding of moderate intermediate clinical severity | 100 | 92.6|
| ≥1 finding of moderate intermediate clinical severity, or ≥1 risk-factor | 105 | 97.2|

**NOTES:**

1. Data refer to percent of total number of patients
2. Underlying risk factors for severe influenza are specified in Table 1.

COPD, chronic obstructive pulmonary disease; HGB, Haemoglobin; PaO2, partial pressure of oxygen in arterial blood; SpO2, Oxygen saturation; WBC, white blood cells.

doi:10.1371/journal.pone.0042940.t003
outcomes (e.g., ICU transfer or death), a longer period of hospitalization and, again, higher costs.

Once organized and the staff properly trained, a medical unit suitable to provide both general and intermediate specialized care for influenza may represent a flexible solution to comply with the demands for the appropriate level of hospital care required. For instance, such a medical unit might normally serve as a general-care specialized ward capable, however, of assisting sporadic patients requiring an intermediate-care due to acute seasonal influenza or other infectious diseases; nevertheless, this same medical unit would be ready to be upgraded, either entirely or partially, to an HDU (e.g., by implementing a higher nurse:patient ratio) during influenza pandemics or any other infectious disease epidemic which might determine a patient burden necessitating an intermediate-level of care. It should be emphasized, however, that our organizational model, although appearing to well work during the 2009pI, could be overwhelmed in case of future pandemics caused by more virulent viral strains, with more cases requiring intensive care; on the other hand, it is this worse scenario which especially encourages investigation and implementation of all possible strategies, including the specialized medical units proposed herein, which would be capable of reducing the burden of critically ill patients admitted to ICUs.

As to which type of medical unit is more suitable to be designated and organized to effectively care for moderate to intermediate 2009pI illness, this obviously depends on the local organization and available resources. Existing non-ICU/non-HDU wards dedicated to managing emergency oxygen use and NIV on a regular basis (for example, respiratory wards, emergency wards, or other critical care areas [51–53]) could well serve this purpose. However, it is essential to ensure that these settings are structurally competent to enable infection control measures and that the staff is trained to properly manage serious disease complications; in addition, the availability of an infectious diseases specialist consultation would be appropriate. For these reasons, IDUs may represent an effective and efficient option, as these settings are already capable of specialized management of influenza and comply with both structural and organizational requirements for infection control.

Acknowledgments

The authors are grateful to: Ms. Paulene Butts for her assistance in the preparation of the manuscript, Salvatore Grasso (Dipartimento dell’Emergenza e Trapianti d’Organo, Sezione di Anestesiochirurgia e Rianimazione, Università degli Studi, Bari, Italy) for his advises in data analysis, Francesco Stea (Dipartimento dell’Emergenza, A.O.U. Policlinico, Bari, Italy) for the cooperation of the Emergency Department, and the following physicians in the care of inpatients of the IDU and contribution to data collection: Silvia Coppiola, Nicoletta Ladina, Vincenzo Lamargese, Michele Milicia, Fabio Sguinoro.

Author Contributions

Analyzed the data: SC GB GA. Wrote the paper: SC GB GA LM. Conceived and designed the study: GA SC LM. Collected and recorded the data: GB ADP GDC.

References

1. European Centre for Disease Prevention and Control (ECDC) (2010) The 2009 A(H1N1) pandemic in Europe. A review of the experience. Available: http://ecdc.europa.eu/en/publications/Publications/101108_SPR_pandemic_experience.pdf via the Internet. Accessed 31 March 2012.

2. Webb SA, Potula V, Seppol I, Bellomo R, Bailey M, et al. (2009) Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 361:1925–1934.

3. Poirpil W, Hell M, Herkner H, Stoisser B, Fritsche G, et al. (2011) Clinical aspects of 2009 pandemic influenza A (H1N1) virus infection in Austria. Influenza and Other Respiratory Viruses 5:341–352.

4. Van Kerkhove MD, Vandemeule CA, Shinde V, Jaramillo Gutierrez G, Koukounari A, et al. (2011) WHO Working Group for Risk Factors for Severe H1N1pdm Infection. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med 8(7):e1001053.

5. Santa-Olalla Peralta P, Cortes-Garcia M, Vicente-Herrero M, Castillejo Villamandos C, Arias-Bohigas P, et al. (2010) Risk factors for disease severity among hospitalised patients with 2009 pandemic influenza A (H1N1) in Spain, April–December 2009. Euro Surveill 15: pii:19667.

6. Jain S, Kamimoto L, Bradley SM, Schmitz AM, Benoit SR, et al. (2009) 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team. Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. N Engl J Med 361(20): 1955–1964. Epub 2009 Oct 8.

7. Centers for Disease Control and Prevention (CDC) (2009) Updated CDC Estimates of 2009 H1N1 Influenza Cases, Hospitalizations and Deaths in the United States, April 2009 – April 10, 2010. Available: http://www.cdc.gov/h1n1flu/pdf/CDC_2009_H1N1_Est_PDF_MAY_4_10_fulltext.pdf via the Internet. Accessed 31 March 2012.

8. Campbell A, Rodin R, Kropp R, Mao Y, Hong Z, et al. (2010) Risk of severe outcomes among patients admitted to hospital with pandemic (H1N1) influenza. CMAJ 9:1082:3: 349–355.

9. World Health Organization (WHO): Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and other Influenza Viruses Revised 2010 – Part I – Recommendations. Available: http://www.who.int/csr/resources/publications/swineflu/h1n1_use_antivirals_20090820/en/index.html via the Internet. Accessed 31 March 2012.

10. Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, et al. (2009) Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 302:1872–1879.

11. Nguyen-Van-Tam JS, Openheir PJ, Hashim A, Gadd EM, Lim WS, et al. (2009) Risk factors for hospitalisation and poor outcome with pandemic A H1N1 influenza: United Kingdom first wave (May–September 2009). Thorax 65:645–651.

12. Zarychanski R, Stuart TL, Kuman A, Doucette S, Elliott L, et al. (2010) Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection. CMAJ 182: 257–64.

13. World Health Organization (2010) Evolution of a pandemic: A(H1N1) 2009, April 2009–March 2010. Geneva. Available: http://www.who.int/influenza/resources/publications/evolution_pandemic_Ah1n1/en/index.html via the Internet. Accessed 31 March 2012.

14. Louie JK, Arora M, Winters K, Jean C, Gavali S, et al. (2009) Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 302:1906–1902.

15. Gilca R, De Serres G, Boulainn N, Oehlschmme N, Papenburg J, et al. (2011) Risk factors for hospitalization and severe outcomes of 2009 pandemic H1N1 influenza in Quebec, Canada. Influenza Other Respir Viruses 5(4):247–255.

16. Bassetti M, Parisini A, Calzi A, Pallavicini FM, Cassola G, et al. (2011) Risk factors for severe complications of the novel influenza A (H1N1): analysis of patients hospitalized in Italy. Clin Microbiol Infect 17:247–250.

17. Legislazione Italiana del Farmaco (2008) Determinazione 20 marzo 2008. Linee guida per la classificazione e conduzione degli studi osservazionali sui farmaci. Gazzetta Ufficiale della Repubblica Italiana, 31/03/2008; serie generale n. 76:68–74. Available: http://oss-uper.clin.agenziamarfarmaco.it/normativa/direttive_OSfS-000099-000000.pdf via the Internet. Accessed 31 March 2012.

18. Ministero del Lavoro della Salute e delle Politiche Sociali Dipartimento della previzione e della comunicazione Direzione generale della prevenzione sanitaria Ufficio V – Malattie Infettive e Profilassi Internazionale Roma (2009) Circolare N. 0031402. Aggiornamento delle indicazioni relative alla prevenzione, sorveglianza e controllo della nuova Influenza da virus influenza A/H1N1v. 27/07/2009. Available: http://www.normativaasannitaria.it/norma-pdf/0000/29529_1.pdf via the Internet. Accessed 31 March 2012.

19. Centers for Disease Control and Prevention (CDC) (2009). Evaluation of rapid influenza diagnostic tests for detection of novel influenza A(H1N1) Virus—United States, 2009. MMWR Morb Mortal Wkly Rep 58:626–629.

20. Centers for Disease Control and Prevention (CDC) (2009). Evaluation of rapid influenza diagnostic tests for detection of novel influenza A(H1N1) Virus—United States, 2009. MMWR Morb Mortal Wkly Rep 58:626–629.

21. National Center for Immunization and Respiratory Diseases (2009) Use of influenza A (H1N1) 2009 monovalent vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 58(RR-10): 1–8.

22. Fiore A, Shay D, Broder K, Uyeki T, Mootrey G, et al. (2009) Prevention and control of influenza, recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 57(RR-7): 1–60.
23. Mererekere J, Cotter S, Nicolai A, Levy-Bruhl D, Ferro A, et al. (2008) National seasonal influenza vaccination survey in Europe, 2008. Euro Surveill 13: pii:19017.

24. Lim WS, Baudouin SV, George RG, Hill AT, Jamieson C, et al. (2009) Pneumonia Guideline Committee of the BTS Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 64 Suppl 3ii:–53.

25. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, et al. (2007) Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44:suppl 2:27–72.

26. White DB, Angus DC (2009) Preparing for the sickest patients with 2009 influenza A(H1N1). JAMA 302:1905–1906.

27. Staudinger T (2010) New flu (H1a1): phantom or intensive medicine super-GAU—a viewpoint from the Austrian reality. Wien Klin Wochenschr 122:5–5.

28. World Health Organization (WHO) (2009) Clinical management of human infection with pandemic (H1N1) 2009: revised guidance November 2009. Available: http://www.who.int/csr/resources/publications/swineflu/clinical_management/en/index.html via the Internet. Accessed 31 March 2012.

29. U.K. Department of Health (DH) (2009) Pandemic H1N1 2009 Influenza: Clinical Management Guidelines for Adults and Children – Updated December 2009. Available: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@@en/@ps/@sta/@p erf/documents/digitalasset/dh_110617.pdf via the Internet. Accessed 31 March 2012.

30. Yang NG, Cao B, Liang LR, Li XJ, Xiao YH, et al. (2012) National Influenza A Pandemic (H1N1) 2009 Clinical Investigation Group of China. Antiviral therapy and outcomes of patients with pneumonia caused by influenza A pandemic (H1N1) virus. PLoS One 7: e29652. Epub 2012 Jan 20.

31. Charles PG, Johnson PD, Collignon PJ. (2009) Can we readily identify patients who need antibiotics in a severe influenza pandemic? Med J Aust 191(9):517–518.

32. Morens DM, Tauxeberger JK, Fauci AS. (2009) Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 198:962–970.

33. Schwarzmann SW, Adler JL, Sullivan RJ Jr, Marine WM. (1971) Bacterial pneumonia during the Hong Kong influenza epidemic of 1960–1969. Arch Intern Med 127:1037–1041.

34. Tsagrelis C, Mohammad M, Fraznich HS, Dellingger RP, Marshene D, et al. (2010) Secondary bacterial pneumonia due to Staphylococcus aureus complicating 2009 influenza A (H1N1) viral infection. Infection 38:237–239.

35. Gill JR, Sheng ZM, Eby SF, Guiney DG, Beasley MB, Suh J, et al. (2010) Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch Pathol Lab Med 134:255–243.

36. Centers for Disease Control and Prevention (CDC) (2009) Hospitalized patients with novel influenza A (H1N1) virus infection—California, April-May, 2009. MMWR Morb Mortal Wkly Rep 58:536–541.

37. Centers for Disease Control and Prevention (CDC) (2009) Intensive care patients with severe novel influenza A (H1N1) virus infection—Michigan, June 2009. MMWR Morb Mortal Wkly Rep 58:749–5.

38. Centers for Disease Control and Prevention (CDC) (2009) Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) - United States, May-August 2009. MMWR Morb Mortal Wkly Rep 58(38):1071–1074.

39. Parham MJ (2005) Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 18:125–131.

40. Amsden GW (2003) Anti-inflammatory effects of macrolides—an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 55:10–21.

41. Sato K, Suga M, Akaie T, Fujii S, Muranaka H, Doi T, et al. (1998) Therapeutic effect of erythromycin on influenza virus-induced lung injury in mice. Ann J Respir Crit Care Med 157:853–857.

42. Turia M, Kurokaawa M, Imakita M, Fukuda Y, Watanabe Y, et al. (2001) Early augmentation of interleukin (IL)-12 level in the airway of mice administered orally with clarithromycin or intranasally with IL-12 results in alleviation of influenza infection. J Pharmacol Exp Ther 298:362–368.

43. Ninomiya K. (2005) Beneficial effects of macrolide antibiotics on children with influenza. Jpn J Antibiot 58(suppl):A84–6.

44. Leelarasamee A, Jongwutivu U, Punthavathana P, Sirintantikorn S (2008) Fulminating influenza pneumonia in the elderly: a case demonstration. J Med Assoc Thai 99:294–299.

45. Miyamoto D, Hasegawa S, Sriswilaijaroen N, Yingakmongkon S, Hiramatsu H, et al. (2008) Clarithromycin inhibits progeny virus production from human influenza virus-infected host cells. Biol Pharm Bull 31:217–222.

46. Bermejo-Martin JF, Kelvin DJ, Eiros JM, Castorena J, et al. (2009) Macrolides for the treatment of severe respiratory illness caused by novel H1N1 swine influenza viral strains. J Infect Dev Ctries 3:159–161.

47. De la Tabla VO, Maia M, Antespuela P, Martin C, Gazquez G, et al. (2010) Comparison of combined nose-throat swabs with nasopharyngeal aspirates for detection of pandemic influenza A/H1N1 2009 virus by real-time reverse transcriptase PCR. J Clin Microbiol 48(10):3492–3495.

48. Ministero della Salute (2010) Circolare influenza 2010–2011 del 29/07/2010. Available: http://www.normativaasanitaria.it/normsan-pdf/0000/29529_1.pdf via the Internet. Accessed 31 March 2012.

49. European Centre for Disease Prevention and Control (ECDC) (2010) Influenza surveillance in Europe 2008/09. Available: http://ecdc.europa.eu/en/publications/Publications/1005_SUR_Influenza_Europe.pdf via the Internet. Accessed 31 March 2012.

50. World Health Organization (WHO) (2009) Human infection with pandemic (H1N1) 2009 virus: updated interim WHO guidance on global surveillance, 10 July 2009. Available: http://www.who.int/csr/disease/swineflu/guidance/surveillance/WHO_case_definition_swine_flu_2009_07_10.pdf via the Internet. Accessed 31 March 2012.

51. British Thoracic Society Standards of Care Committee (2002) Non-invasive ventilation in acute respiratory failure. Thorax 57:192–211.

52. British Thoracic Society, Royal College of Physicians London, Intensive Care Society (2008) The Use of Non-Invasive Ventilation in the management of patients with chronic obstructive pulmonary disease admitted to hospital with acute type II respiratory failure (with particular reference to Bilevel positive pressure ventilation). Available: http://www.brit-thoracic.org.uk/guidelines.aspx via the Internet. Accessed 31 March 2012.

53. O'Driscoll BR, Howard LS, Davison AG, on behalf of the British Thoracic Society. Emergency Oxygen Guideline Development Group, a subgroup of the British Thoracic Society Standards of Care Committee (2008) Guideline for emergency oxygen use in adult patients. Thorax 63:suppl VI:v1–v68.